Phase I Study of Heat Activated Doxorubicin HCl Liposome Combined With Radiofrequency Ablation in Patients With Primary or Metastatic Tumors of the Liver
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Related Information Registry Information
Alternate Title
Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
NCI-04-C-0263 CELSION-10403101, NCT00093444
|
|
|
Objectives - Determine the maximum tolerated dose of heat activated doxorubicin HCl liposome when combined with radiofrequency ablation in patients with primary or metastatic tumors of the liver.
- Determine the pharmacokinetics and pharmacodynamics of this drug in these patients.
Entry Criteria Disease Characteristics:
- Histologically confirmed tumor of the liver
- Primary or metastatic disease
- No more than 4 lesions
- No single lesion > 7 cm in maximum diameter
- Not a candidate for curative surgical resection due to tumor histology or prior surgery
Prior/Concurrent Therapy:
Biologic therapy - No concurrent interferon
- No live vaccines (for immunosuppressed patients only) during and for 30 days after study treatment
Chemotherapy Endocrine therapy Radiotherapy Surgery - See Disease Characteristics
Other - More than 3 weeks since prior therapy for liver tumor(s)
- More than 3 weeks since prior systemic therapy for non-life-threatening extrahepatic disease and recovered
- No other concurrent systemic therapy
- No administration of any of the following medications during and for 30 days after study treatment:
- Cyclosporine
- Phenobarbital
- Phenytoin
- Streptozocin
- No concurrent administration of any of the following medications:
- Amphotericin B by injection
- Antithyroid agents for overactive thyroid
- Azathioprine
- Chloramphenicol
- Colchicine
- Flucytosine
- Ganciclovir
- Plicamycin
- Zidovudine
- Probenecid
- Sulfinpyrazone
Patient Characteristics:
Age Performance status Life expectancy Hematopoietic - Platelet count ≥ 75,000/mm3
- WBC ≥ 1,500/mm3
- Hemoglobin ≥ 10 g/dL (transfusions to attain levels ≥ 10g/dL allowed)
Hepatic - Bilirubin ≤ 2.0 mg/dL
- PT or PTT ≤ 1.5 times control (except for patients receiving anticoagulation therapy for an unrelated medical condition [e.g., atrial fibrillation])
Renal Cardiovascular - See Hepatic
- Ejection fraction ≥ 50% by MUGA
- No congestive heart failure
- No myocardial infarction within the past 6 months
- No cerebral vascular accident within the past 6 months
- No life-threatening cardiac arrhythmia
Other - Weight < 136 kg
- Glucose ≤ 300 mg/dL
- No uncontrolled diabetes
- No known serious uncontrolled reaction (e.g., anaphylaxis) to contrast agents used in this study
- No known allergy to egg or egg products
- No other serious medical illness
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
Expected Enrollment 30Approximately 30 patients will be accrued for this study within 2 years. Outcomes Primary Outcome(s)Maximum tolerated dose of heat-activated doxorubicin HCL liposome Pharmacokinetics and pharmacodynamics of heat-activated doxorubicin HCL liposome at 15, 30, 45, 60, 75, and 90 minutes; 2, 3, 4, 6, 24, and 46 hours; and 4 and 8 days following infusion
Secondary Outcome(s)Effects of ablative therapy on tumor blood flow and tumor vascular density as measured by MRI at 28 days following study completion
Outline This is a dose-escalation study of heat activated doxorubicin HCl liposome. Patients receive doxorubicin HCl liposome IV over 30 minutes. Approximately 15 minutes after the beginning of the doxorubicin HCl liposome infusion, patients undergo radiofrequency ablation with needles inserted into the tumor(s) and heated to the target temperature for approximately 12-60 minutes. Cohorts of 3-6 patients receive escalating doses of heat activated doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD. Patients are followed at 28 days, every 3 months for 1 year, and then every 6 months for 2 years.
Trial Contact Information
Trial Lead Organizations NCI - Center for Cancer Research | | | Bradford Wood, MD, Protocol chair | | | |
Related Information Web site for additional information
Registry Information | | Official Title | | A Phase I Dose Escalation Study Of Heat Activated Liposome Delivery Of Doxorubicin And Radiofrequency Ablation Of Primary And Metastatic Tumors Of The Liver | | Trial Start Date | | 2004-09-07 | | Registered in ClinicalTrials.gov | | NCT00093444 | | Date Submitted to PDQ | | 2004-08-16 | | Information Last Verified | | 2007-04-29 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |